Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- (-) Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- (-) Health Spend Management
- (-) High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- (-) Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Display Only
Showing 42 Results
The Dollar or Disease Burden: Caps on Healthcare Spending May Save Money, but at What “Cost” to Patients?
This study assessed the potential effects of budget caps design on disease burden and cost savings to help budget decision makers understand which budget cap features minimize impact to patient…
Racial and Socioeconomic Disparities: Ignoring Inequitable Benefit Design Is Not an Option
In a new commentary published in BenefitsPro, Kimberly Westrich, NPC Vice President for Health Services Research, and Bruce Sherman, MD, medical advisor for the National Alliance of Healthcare…
How Can Payers Advance Patient-reported Measures in Oncology, and Why Should We Care?
A peer-reviewed study describes the current state of patient-reported measures and patient-reported performance measures in oncology, the barriers to implementation, and actionable recommendations…
NPC Comments on CMS Best Price and Barriers to Value-Based Arrangements
NPC outlines how Medicaid Best Price poses a barrier to implementing value-based arrangements and hinders innovation in payment and delivery systems, which can make it difficult for patients to…
Accumulating Barriers to Care: Double Jeopardy for US Patients
In a column for PharmaBoardroom, Dan Leonard, National Pharmaceutical Council President and CEO, Kimberly Westrich, Vice President of Health Services Research, and Brian Sils, Senior Research…
Good News for Patients With High-Deductible Health Plans
In his commentary for Specialty Pharmacy Times, NPC President and CEO Dan Leonard explains how research supported by NPC and conducted by VBID Health demonstrates the health and cost benefits of…
Best Ideas Aren’t Always (or Often) From Washington
In his latest commentary for Chain Drug Review, National Pharmaceutical Council President and CEO Dan Leonard explores the health care concerns and ideas for improvement discussed at recent regional…
U.S. Care Pathways: Continued Focus on Oncology and Outstanding Challenges
A peer-reviewed study assessed changes in development, implementation, and evaluation of care pathways, and reviewed the latest evidence on integration of pathways with value-based care initiatives…
Uptake and Federal Budgetary Impact of Allowing Health Savings Account-eligible High Deductible Health Plans to Cover Chronic Disease Drugs and Services Pre-deductible
This report examines the net federal budgetary impact allowing Health Savings Account-eligible HDHPs to expand pre-deductible coverage to include chronic disease services.
Integrating Data for Better Care Management
To accelerate the ability of care management programs to use data to combat rising health care costs, while ensuring patient access to innovative treatments that can improve outcomes, NPC sponsored…
What's Been the Bang for the Buck? Cost-Effectiveness of Health Care Spending Across Selected Conditions in the US
This study was designed to assess whether increased medical intervention spending on prevalent chronic conditions has been a good investment over time.
Financial Impact of HSA-HDHP Reform to Improve Access to Chronic Disease Management Medications
According to an issue brief from VBID Health, providing pre-deductible coverage for medicines used to treat common chronic conditions could lower out-of-pocket costs and increase medication adherence…
Could expanding pre-deductible coverage help those with chronic conditions?
According to a new issue brief from VBID Health, providing pre-deductible coverage for medicines used to treat common chronic conditions could lower out-of-pocket costs and increase medication…
Learn More About Oncology Clinical Pathways in Webinar from Turning the Tide Against Cancer
Ideally, clinical pathways can be a useful tool to help clinicians make sense of quickly evolving science, ensure patients receive the right care at the right time, help standardize care and limit…
Concerns Around Budget Impact Thresholds: Not All Drugs Are The Same
A study published in Value in Health explores the potential impact of using budget thresholds as budget caps (e.g., cannot spend more than a set dollar amount) for individual drugs.
A Dynamic Approach to Consumer Cost-Sharing for Prescription Drugs
The level of consumer cost-sharing for higher cost medication should be aligned with the clinical value – not solely the price – when lower cost alternatives do not produce the desired patient…
Care Pathways in U.S. Health Care Settings: Current Successes and Limitations, and Future Challenges
Care pathways, also known as clinical pathways or integrated care pathways, are typically characterized as a method for managing patient care based on clinical practice guidelines, with the main…